8-K current report · filed Aug 3, 2026

Indivior Pharmaceuticals, Inc. (INDV) 8-K Current Report: August 3, 2026

Item 1.01Item 7.01Item EX-99.1Item EX-99.2Item EX-99.3INDV overview

Short answer

Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). Indivior agreed to acquire Supernus in an all-stock merger at a 1.5401 exchange ratio per Supernus share.

Indivior Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Indivior agreed to acquire Supernus in an all-stock merger at a 1.5401 exchange ratio per Supernus share
  • Indivior shareholders retain approximately 56.5% ownership, while Supernus shareholders receive approximately 43.5% of the Combined Company
  • $1.0 billion special dividend creates substantial funding needs, supported by Citibank’s committed $650 million senior secured term loan
  • Combined Company to be renamed Supernus, Inc., trade on Nasdaq under “SUPN,” with Jack Khattar as CEO and Timothy Dec as CFO
  • Closing requires shareholder approvals, regulatory clearance and other conditions, with termination fees of $174.0 million for Indivior and $101.0 million for Supernus

Item 7.01 · Regulation FD Disclosure

  • Joint Indivior–Supernus press release announces execution of a merger agreement
  • Merger terms and transaction implications contained in Exhibit 99.3
  • Filing signals a potentially material corporate transaction requiring investor review of deal conditions and consideration

Item EX-99.1 · Exhibit EX-99.1

  • Voting agreement supports Indivior’s proposed acquisition of Supernus through a stockholder commitment to approve share issuance and merger transactions
  • Stockholder must vote against competing proposals and actions that could delay or impede the merger
  • Transfer restrictions and stop-transfer instructions limit disposition of covered Indivior shares until approval, termination, or closing
  • Agreement expires upon merger termination, required approval, closing, or an adverse recommendation change
  • Stockholder monetary damages capped at covered shares multiplied by $38.85; Supernus retains specific-performance remedies

Item EX-99.2 · Exhibit EX-99.2

  • Indivior secured a binding voting commitment supporting its proposed merger with Supernus, improving transaction-closing certainty
  • Stockholder must vote all covered Supernus shares for the merger and against competing proposals or delay tactics
  • Transfer restrictions and stop-transfer instructions prevent disposal or inconsistent voting of covered shares before approval or termination
  • Commitment ends upon shareholder approval, deal termination, adverse recommendation change, or merger closing
  • Stockholder litigation rights are limited for merger-related challenges, while monetary damages are capped at merger consideration value

Item EX-99.3 · Exhibit EX-99.3

  • All-stock merger creates diversified CNS company with approximately $2.2B revenue and 11 commercial medicines
  • Expected $125M annual cost synergies support pro forma adjusted EBITDA of $888M
  • Indivior holders receive $1.0B special cash dividend, funded by $650M term loan and existing cash
  • Post-closing ownership: Indivior holders 56.5%, Supernus holders 43.5%; Jack Khattar to lead combined company
  • Expected fourth-quarter 2026 closing remains subject to shareholder and regulatory approvals

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Indivior Pharmaceuticals, Inc. 8-K filings

Get the next INDV 8-K as it lands

Follow INDV for push alerts, or ask the research agent what this filing means.